# A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

> **NCT07268053** · EARLY_PHASE1 · RECRUITING · sponsor: **Nader Sanai** · enrollment: 15 (estimated)

## Conditions studied

- Glioblastoma (GBM)
- Brain Metastasases

## Interventions

- **DRUG:** Risvutatug rezetecan

## Key facts

- **NCT ID:** NCT07268053
- **Lead sponsor:** Nader Sanai
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-11
- **Primary completion:** 2027-07
- **Final completion:** 2029-07
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07268053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07268053, "A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07268053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*